While in the secondary analysis, the less conservative but clinically meaningful criterion of secure reaction (defined being a fifty% or more reduction in MADRS from baseline for two months) was used. In the patients who realized steady reaction, twenty five.eight% during the esketamine group and 57.six% while in the placebo https://rachelo899ndq7.fliplife-wiki.com/user